Table 5.
Least square mean changes in total cholesterol, high-density lipoprotein cholesterol and triglyceride from baseline after 8 weeks of treatment
| Summary of each treatment | FMS/RSV vs. FMS | FMS/RSV vs. RSV | |||||
|---|---|---|---|---|---|---|---|
| FMS/RSV (N = 46) |
FMS (N = 45) |
RSV (N = 44) |
LSM difference (SE) | P-valuea | LSM difference (SE) | P-valuea | |
| Total cholesterol | −36.13 (1.77) | −3.62 (1.92) | −35.99 (1.95) | −32.51 (2.44) | −0.14 (2.45) | ||
| 95% CI | (−39.63, −32.64) | (−7.41, 0.17) | (−39.86, −32.13) | (−37.34, −27.69) | <0.001 | (−4.99, 4.71) | 0.954 |
| HDL-C | 10.24 (2.63) | −3.22 (2.86) | 13.43 (2.95) | 13.47 (3.63) | −3.19 (3.67) | ||
| 95% CI | (5.03, 15.45) | (−8.88, 2.43) | (7.60, 19.26) | (6.28, 20.65) | <0.001 | (−10.46, 4.08) | 0.387 |
| Triglyceride | −12.78 (5.79) | 20.30 (6.27) | −13.65 (6.41) | −33.08 (7.97) | 0.88 (8.06) | ||
| 95%CI | (−24.24, −1.32) | (7.89, 32.71) | (−26.34, −0.96) | (−48.86, −17.30) | <0.001 | (−15.08, 16.83) | 0.914 |
HDL-C high-density lipoprotein cholesterol, FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, LSM least square mean, SE standard error
aComparison between the combination therapy and monotherapy was analyzed by ANCOVA model adjusted for baseline values, age, gender and smoking status